Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

All Articles

A Disney Childhood Until Cancer Enters Stage Left
Cathy Sherman Freeman’s father, who was Head of Publications at Walt Disney Studios, passed away of gastrointestinal stromal tumor (GIST), the same rare cancer she was diagnosed with several years ago. Read More ›

Regaining My Life After a Diagnosis of Non-Hodgkin Lymphoma
NHL survivor Carlo Lopez shares his personal experience with cancer and his goal of becoming an oncology nurse to offer other people the knowledge and experience he gained as a patient. Read More ›

Coffee and Cancer—Again?
A new law in California revives the debate about coffee and cancer. However, according to the American Institute for Cancer Research, hundreds of studies show that coffee doesn’t cause cancer in humans. Read More ›

Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations


Erleada First Drug Approved for Patients with Nonmetastatic Prostate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer. Read More ›

Tagrisso Now Approved as First Treatment for Metastatic NSCLC and EGFR Mutations

Verzenio Approved as Initial Treatment for Metastatic Breast Cancer
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer. Read More ›

Imfinzi Approved to Reduce Cancer Progression in Stage III Lung Cancer

Tagrisso Now Approved as First Treatment for Metastatic NSCLC and EGFR Mutations

Page 118 of 165